GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Net Income Including Noncontrolling Interests

Cytophage Technologies (TSXV:CYTO) Net Income Including Noncontrolling Interests : C$-1.90 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Cytophage Technologies's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was C$-4.28 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was C$-1.90 Mil.


Cytophage Technologies Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Cytophage Technologies's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Net Income Including Noncontrolling Interests Chart

Cytophage Technologies Annual Data
Trend Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
-3.24 -0.71 0.02

Cytophage Technologies Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial 2.13 -1.16 -0.98 3.36 -4.28

Cytophage Technologies Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cytophage Technologies Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytophage Technologies (TSXV:CYTO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.

Cytophage Technologies (TSXV:CYTO) Headlines